$-0.66 EPS Expected for AnaptysBio, Inc. (ANAB)

October 13, 2018 - By olga

Analysts expect AnaptysBio, Inc. (NASDAQ:ANAB) to report $-0.66 EPS on November, 6.They anticipate $0.21 EPS change or 46.67 % from last quarter’s $-0.45 EPS. After having $-0.57 EPS previously, AnaptysBio, Inc.’s analysts see 15.79 % EPS growth. The stock decreased 1.26% or $1 during the last trading session, reaching $78.64. About 355,536 shares traded. AnaptysBio, Inc. (NASDAQ:ANAB) has risen 165.85% since October 13, 2017 and is uptrending. It has outperformed by 150.23% the S&P500.

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company has market cap of $2.06 billion. The company??s proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases. It currently has negative earnings. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize an anti-PD-1 antagonist antibody and an anti-TIM-3 antagonist antibody (TSR-022), which are under clinical development; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 checkpoint agonist antibody (CC-90006) that is in clinical stage.

More notable recent AnaptysBio, Inc. (NASDAQ:ANAB) news were published by: Fool.com which released: “Here’s Why AnaptysBio Inc Rose as Much as 18.5% Today” on September 24, 2018, also Globenewswire.com with their article: “AnaptysBio Announces Pricing of Public Offering of Common Stock” published on September 25, 2018, Seekingalpha.com published: “AnaptysBio prices public offering of common stock” on September 26, 2018. More interesting news about AnaptysBio, Inc. (NASDAQ:ANAB) were released by: Fool.com and their article: “Here’s Why AnaptysBio Rose 12.6% in September” published on October 11, 2018 as well as Globenewswire.com‘s news article titled: “Research Report Identifies AnaptysBio, Imperial Oil, Norbord, 3D, Apple Hospitality REIT, and Pinnacle Foods with …” with publication date: October 08, 2018.

AnaptysBio, Inc. (NASDAQ:ANAB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News